![]() | ![]() |
Formats:
|
||||||||||||||||||||||
Copyright © American Society for Investigative Pathology Pericytes and Perivascular Fibroblasts Are the Primary Source of Collagen-Producing Cells in Obstructive Fibrosis of the Kidney From the Laboratory of Inflammation Research,* Renal Division, Brigham & Women’s Hospital and Harvard Medical School, Boston, Massachusetts; Department of Medicine,† National Taiwan University Hospital, College of Medicine, Taipei, Taiwan; and University of California, San Diego, School of Medicine,‡ La Jolla, California Accepted August 21, 2008. This article has been cited by other articles in PMC.Abstract Understanding the origin of scar-producing myofibroblasts is vital in discerning the mechanisms by which fibrosis develops in response to inflammatory injury. Using a transgenic reporter mouse model expressing enhanced green fluorescent protein (GFP) under the regulation of the collagen type I, α 1 (coll1a1) promoter and enhancers, we examined the origins of coll1a1-producing cells in the kidney. Here we show that in normal kidney, both podocytes and pericytes generate coll1a1 transcripts as detected by enhanced GFP, and that in fibrotic kidney, coll1a1-GFP expression accurately identifies myofibroblasts. To determine the contribution of circulating immune cells directly to scar production, wild-type mice, chimeric with bone marrow from coll-GFP mice, underwent ureteral obstruction to induce fibrosis. Histological examination of kidneys from these mice showed recruitment of small numbers of fibrocytes to the fibrotic kidney, but these fibrocytes made no significant contribution to interstitial fibrosis. Instead, using kinetic modeling and time course microscopy, we identified coll1a1-GFP-expressing pericytes as the major source of interstitial myofibroblasts in the fibrotic kidney. Our studies suggest that either vascular injury or vascular factors are the most likely triggers for pericyte migration and differentiation into myofibroblasts. Therefore, our results serve to refocus fibrosis research to injury of the vasculature rather than injury to the epithelium. The origin of scar-producing cell(s) in the kidney is of primary importance to understanding the mechanisms by which fibrosis develops in response to inflammatory injury. In the healthy kidney as in other organs, no clear endogenous precursor of the myofibroblast has been thought to exist.1 Derivation of myofibroblasts from bone marrow-derived CD34+ circulating cells known as fibrocytes has been proposed in several studies, and conflicting data have been published suggesting that a separate population of bone marrow-derived myofibroblasts contribute to interstitial fibroblasts in the kidney.2,3,4 Injured epithelial cells undergoing epithelial to mesenchymal transition (EMT) have been proposed to contribute to kidney myofibroblasts as well, with some studies suggesting epithelial cells are the major source of fibroblasts in the kidney and elsewhere.5,6 We have recently reported using robust, reproducible genetic fate mapping techniques in vivo that epithelial cells make no significant contribution to myofibroblasts in mouse kidney fibrosis (Humphreys et al, manuscript submitted for publication). Our recent report suggested that fresh investigation of the source of myofibroblasts in the kidney was merited. Myofibroblasts are the cell type that generates and deposits collagen-I and collagen-III rich pathological extracellular matrix leading to irreversible fibrosis and causing organ dysfunction. Antibodies against the intermediate filament α-SMA has been widely used as a marker for collagen producing myofibroblasts, and other less-widely accepted markers such as the transcription factor S100A4 have been reported to label myofibroblasts.5 However none of these markers is unique to myofibroblasts and none labels proteins that define the cell functionally. One unique characteristic of fibroblasts is that they generate and deposit into the extracellular matrix collagen-I. We have previously generated transgenic mice expressing enhanced green fluorescent protein (EGFP) in cells producing the collagen type I, α 1 (coll1a1) transcript (coll-GFP mice).7,8 These mice express a single copy of 3.5 kb of the 5′ coll1a1 promoter, 0.5 kb of the 3′ uncoded region and four upstream enhancers, driving EGFP expression, and have been shown to label with high sensitivity and specificity collagen-I α1 producing cells7 (Figure 1A)
We have used this mouse model to study collagen (collagen-I, α 1)-producing cells in kidney disease. Our studies indicate that a population of pericytes, subendothelial cells that regulate microvascular integrity in the peritubular capillary network, and also perivascular fibroblasts are a major source of myofibroblasts, and that transcription factors including Snail homologue 1 (Snai1) and inhibitor of DNA binding 1 (Id1) are induced during differentiation of pericytes into myofibroblasts in the ureteral obstruction model of fibrosis in the kidney. Materials and Methods Coll-GFP Mouse Model Coll-GFP transgenic mice were generated and validated as previously described on the C57BL/6 background.7,8 In brief, 3.2 kb of the collagen-1 (α1) promoter was cloned as were DNase1 hypersensitivity sites (HS) with enhancer activity from 7 kb and 8 kb 5′ of the promoter. This construct, pCol9GFP-HS4,5 with hypersensitivity sites 4 and 5 positioned immediately 5′ of the promoter and the open reading frame of EGFP 3′ of the promoter yielded highest levels of GFP expression when coll1a1 transcripts were generated. Genotyping was performed as previously described.7,8 All studies were performed under a protocol approved by the Harvard Center for Animal Resources and Comparative Medicine. Bone Marrow Chimerism Bone marrow (BM) chimeric mice were generated as previously described.9 In brief, ten million BM cells from male donors in 200 μl of PBS were injected into the lateral tail vein of lethally irradiated (1000 Rads over 30 minutes) isogenic female recipients and chimerism was confirmed after 6 weeks by fluorescent in situ hybridization of buffy coat cells according to the method described previously.9 Briefly, methanol-acetic acid fixed buffy coat cells were incubated with 1 mol/L sodium thiocyanate (80°C, 10 minutes), then digested with proteinase K (37°C, 15 minutes), incubated with 0.1 mol/L HCl (37°C, 10 minutes), fixed with 4% paraformaldehyde, dehydrated, and air-dried. Fluorescent in situ hybridization mouse Y chromosome-specific probe Star*Fish (Cambio, Cambridge, UK) was added in the manufacturer’s buffer. Slides were heated (80°C, 10 minutes), incubated (16 hours, 37°C), then stringently washed in buffers finally mounted with Vectashield/DAPI (Vector Laboratories). In all cases 100% of leukocytes labeled positively for the Y chromosome. Mouse Models of Fibrosis Adult (12 to 20 weeks) or young (P12) mice (C57BL/6 or coll-GFP) were anesthetized with ketamine/xylazine (100/10 mg/kg, i.p.) before surgery. Unilateral ureteral obstruction (UUO) was performed as previously described (Humphreys et al, unpublished data),10 and kidneys, blood, spleen, and BM, were collected on days 0, 2, 3, 5, 7, 10, and 14. In some experiments unilateral ischemia-reperfusion of the left kidney was exposed through flank incisions was performed as previously described and kidneys harvested at days 0, 7, and 15. Full thickness skin wounds were created by flank incisions using a scalpel blade, and wounds held together with clips. Wounds were dissected on days 2, 3, 5, 7, 10, and 14 for analysis. To determine whether a second inflammatory signal could induce further fibrocyte differentiation, in some experiments, lipopolysaccharaide (6 μg/g, L-2880, Sigma) was injected i.v. for 3 days sequentially following UUO surgery and mice sacrificed on day 7 for analysis. Tissue Preparation and Histology Mouse tissues were prepared and stained as previously described.9,10 Wounded skin was dissected and cut transversely to expose the re-epithelialization of epidermis and the subepidermal granulation tissue and fixed as above. Primary antibodies against the following proteins were used for immunolabeling: αSMA-Cy3 (1:200, clone 1A4, Sigma), CD14, CD11b, CD11c, CD45, CD16/32, MHC class II (I-A/I-E) (1:200, eBioscience), CD34, Ly6C, (Pharmingen) 7/4, (ABD-Serotec), Ki-67 (1:200, clone SP6, Fisher), laminin (1:100, Sigma), NG2 (1:500), platelet-derived growth factor (PDGF) receptor beta (PDGFRβ [1:500], podocin [1:200]; S100A4 [1:200], DAKO, and also Abcam), and WT1 (1:100, Santa Cruz). Fluorescent conjugated affinity purified secondary antibody labeling (1:400 to 1:800, Jackson), mounting with Vectashield/4,6-diamidino-2-phenylindole (DAPI), image capture and processing were performed as previously described.9,10 To study proliferation of coll1a1-GFP cells, 5-bromo-2′-deoxyuridine (BrdU), 50 μg/g was injected i.p. 2 hours before sacrifice. Five-micron cryosections were labeled with chicken anti-GFP antibodies (1:500, Aves Labs), followed by anti-chicken-Cy2 (1:400), after postfixation (4% paraformaldehyde, 1 minute) and incubation with 2N HCl (15 minutes, 37°C), then 0.1 mol/L boric acid (5 minutes, room temperature) twice. Sections were incubated with sheep anti-BrdU (1:200, Abcam), then anti-sheep-Cy3 (1:400) and mounted as above. To study the relationship of coll1a1-producing cells with endothelial cells and capillary basement membrane (CBM), cryosections were labeled with antibody against CD31 (1:200, eBioscience), then Cy3-conjugated secondary antibodies, then anti-laminin antibodies, followed by anti-rabbit-Alexa Fluor350 (1:500, Molecular Probes), and were mounted with Prolong Gold. Quantification of specific cells in tissue sections was performed as previously described.9 In brief, sections were colabeled with DAPI, and Coll1a1-GFP+ cells were identified by blue and green nuclear colocalization; αSMA+, NG2+, or PDGFRβ + cells were identified by greater than 75% of the cell area immediately surrounding nuclei (detected by DAPI) staining positive with Cy3 fluorescence indicative of the antigen expression; Ki-67+ or BrdU+ cells were identified by positive nuclear staining for Cy3 fluorescence. Specific cells were counted in 10 cortical interstitial fields randomly selected at original magnification ×400 per mouse. To study the recruitment of fibrocytes into kidney, spleen, and skin wound, CollIa1-GFP+ cells were counted in six discontinuous whole sagittal sections per BM chimeric mouse studying three mice for each timepoint. Single Cell Preparation from Blood, Spleen, and Kidney Blood (500 μl) was collected from the inferior vena cava in sodium citrate (0.38%). Remaining blood flushed out as described above with ice cold PBS and spleen and kidneys were harvested. Peripheral blood mononuclear cells were isolated from citrated whole blood using Ficoll-Paque PLUS (GE Health care). Spleen was disaggregated by gentle pressure against glass slides, collected in PBS, and aggregates were removed (70 μm filter). Single cells were resuspended in fluorescence-activated cell sorting (FACS) buffer9 after centrifugation. Kidney was decapsulated, diced, incubated (37°C, 1 hour) with liberase (0.5 mg/ml, Roche) and DNase (100U/ml, Roche) in HBSS, and then resuspended in 10 ml of FACS buffer or PBS/0.1% bovine serum albumin, and cells were filtered (30 μm). In some cases leukocyte enrichment was performed by resuspending the single cell suspension in PBS, then overlaying it on a discontinuous percoll gradient (33%, 66% in PBS) and centrifuging (20 minutes, 620 ×g). Kidney fibroblasts or pericytes were purified from the single cell suspension of normal or d7 UUO Coll-GFP mouse kidney (in PBS and 1% bovine serum albumin) by isolating GFP+ cells using FACSAria cell sorting. Flow Cytometric Analysis Single cells (1 × 105) from kidney, peripheral blood mononuclear cells or spleen, were resuspended in FACS buffer9 and incubated with antibodies against CD14, CD11b, CD11c, CD45, MHC class II (I-A/I-E) (PE, 1:200, eBioscience), CD86, CD115, CD34 (PE, 1:200, Pharmingen), CD16/32, F4/80 (APC, eBioscience), CD64 (Alexa Fluor 647, 1:200, BD Biosciences), Ly6-C (FITC, 1:200, BD Biosciences), and 7/4 (Alexa Fluor 647, 1:200, AbD) for 30 minutes, 4°C in the presence of 1% mouse serum. After washing with FACS wash buffer,9 and resuspending in 200 μl FACS buffer, cells were analyzed using BD FACSCalibur flow cytometer. Reverse Transcription-PCR Total RNA was isolated using RNeasy Mini Kit (Qiagen). Purity of determined by A260 to A280. cDNA was synthesized using oligo(dT) and random primers.10 PCR was performed for mouse Twist using specific primers 5′-gAAAATggACAgTCTAgAgACTCTg-3′ and 5′-gTggCTgATTggCAAgACCTCTTg-3′, annealing at 50°C, 35 cycles; Snai1, 5′-AgCCCAACTATAgCgAgCTg-3′ and 5′-CCAggAgAgAgTCCCAgATg-3′; bone morphogenetic protein-7 (Bmp7), 5′-TACgTCAgCTTCCgAgACCT-3′ and 5′-gCTCAggAgAggTTggTCTg-3′, 50°C, 32 cycles; Id1, 5′-CATgAACggCTgCTACTCAC-3′ and 5′-gTggTCCCgACTTCAgACTC-3′, 50°C, 29 cycles; GAPDH 5′-ACTCCACTCACggCAAATTC-3′ and 5′-CACATTgggggTAggAACAC-3′, annealing at 50°C, 23 cycles. Quantitative PCR was determined using methods previously described10 and the following additional primer pairs: Twist 5′-CCCCACTTTTTgACgAAgAA-3′ and 5′-AAAATggAgCCAgTCCACAg-3′, Bmp7 5′-gTACgTCAgCTTCCgAgACC-3′ and 5′-ggTggCgTTCATgTAggA gT-3′. Purity of the pericyte and fibroblast cDNA was confirmed by excluding contamination with transcripts for Kim-1 (epithelial cells), F4/80 antigen, Emr-1 (macrophages), and CD31 endothelial cells.11 Statistical Analysis Error bars are SE of mean. To calculate Td, curves were fit to plots of cell number against time using Prism software (Graphpad). To mathematically calculate the cell cycle time Tc an equation was derived to analyze the increase in cell number with time during which there was a linear increase in the proportion of pericytes entering cell cycle. The equation was derived and solved using Matlab/Simulink software (Mathworks, Natick, MA). Results Pericytes, Perivascular Fibroblasts, and Podocytes Express Coll-GFP in Normal Kidney Mice expressing EGFP under regulation by the coll1a1 promoter and enhancers was generated as previously described7,8 and herein are referred to as Coll-GFP mice (Figure 1A) In Fibrotic Kidney Coll1a1-Producing Cells Correlate Imperfectly with Expression of α-SMA To explore the contribution of coll1a1-producing cells to fibrosis in the kidney we induced UUO, a robust and standardized model for inducing inflammatory fibrosis in the kidney. After 7 days of obstruction in coll-GFP mice many interstitial cells expressed GFP, but GFP was not detected in epithelial cells indicating that epithelial cells were not a source of collagen I (Figure 2A)
Fibrocytes Make a Minor Contribution to the Population of Coll1a1-Producing Cells To explore further the contribution of bone marrow-derived coll1a1-producing cells to fibrosis in the kidney we generated bone marrow (BM) chimeric mice transplanting coll-GFP mouse BM into lethally irradiated recipient wild type mice, then after confirming chimerism, performed UUO surgery to induce kidney fibrosis and kidneys were examined at 0, 2, 3, 5, 7, 10, and 14 days (Figure 3)
The Expansion of the Interstitial Coll1a1-Producing Cell Population in Progressive Fibrosis Can Be Explained by Proliferation of the Initial Population of Pericytes Our previous and current studies indicate myofibroblasts do not derive from kidney epithelial cells or circulating leukocytes (Humphreys et al, manuscript submitted for publication). We were intrigued by the possibility that pericytes might be the source of myofibroblasts because they transcribe the coll1a1 gene basally, and are distributed in along peritubular capillaries and coll1a1-GFP perivascular fibroblasts are distributed along small blood vessels, similarly to myofibroblasts. To study this further we assessed early time-points in the development of UUO to trace pericytes and the appearance of myofibroblasts (Figure 4A) A cell cycle time of 45 hours represents a high cell cycle time compared with those documented for malignant cells or bone marrow cells and means that our studies are therefore consistent with the hypothesis that the majority of the increase in coll1a1+ cells in the kidney interstitium is from proliferation of existing pericytes that migrate from the subendothelial space. There is no unequivocal marker for pericytes, however in other studies, particularly of retinal pericytes, αSMA, desmin, NG2, and antibodies against the 3G5 epitope have been used.12,19,20,21,22,23 We labeled tissues for αSMA and NG2 (Figure 4, E–G) In Neonatal Mice, Pericytes Express NG2 and αSMA, and as Pericytes Differentiate into Myofibroblasts these Markers Are Retained It was surprising to us that pericytes in the adult kidney did not express markers others have reported to label pericytes.19,20,21,22 However, many studies of pericytes have focused on the neonatal eye. Pericytes are reported to lose markers with maturity.12 We hypothesized that kidney pericytes of young mice might retain pericyte markers and co-express coll1a1-GFP, then progressively lose pericyte markers after development. Therefore following UUO surgery in young mice the fate of those pericytes could be followed using established pericyte markers. Kidneys from P12 (neonates 12 days after birth) coll-GFP mice were analyzed, because at this time-point the kidney is fully developed.28 P12 kidneys had many interstitial coll1a1+ cells in the subendothelial area (Figure 5A)
Snai1 and Id1, Transcription Factors Implicated in Fibrosis, Are Induced in Coll1a1-Producing Cells Following Ureteral Obstruction Our studies have identified pericytes as the major source of myofibroblasts in the kidney. To understand potential molecular mechanisms by which pericytes differentiate into myofibroblasts we selected candidate transcription factors or signaling molecules implicated in the appearance of myofibroblasts. Some have been reported to promote EMT in epithelial cells in culture, but our recent studies do not support EMT as a source of fibroblasts in vivo (Humpheys et al, manuscript submitted for publication). The transcription factor Twist has been implicated in tumorigenesis and EMT in vitro.29 In young mice some pericytes and other interstitial cells (but not epithelial cells) express Twist with low-level nuclear expression (Figure 6A)
Discussion These studies have identified two sources of colla1-producing cells in the ureteric obstruction model of kidney fibrosis: fibrocytes and pericytes. The former makes a minor contribution <0.1% of collagen producing cells while the latter intrinsic cell population accounts for the majority of myofibroblasts in the kidney. Using genetic fate mapping techniques we have recently excluded a significant role for epithelial transdifferentiation in vivo in the appearance of myofibroblasts in the ureteral obstruction model of kidney fibrosis (Humphreys et al in submission). While our current studies do not exclude endothelial transdifferentiation we did not find evidence of endothelial cells co-expressing coll1a1-GFP, suggesting that endothelial cells in vivo are not a significant source of myofibroblasts. Our studies do not use genetic fate mapping techniques to follow the differentiation of pericytes in the kidney into myofibroblasts. Nevertheless, kinetic analysis in combination with the use of coll-GFP as a pericyte marker in adult mice strongly indicates that the majority, if not all, myofibroblasts derive from the coll1a1+ pericytes in the interstitium and perivascular fibroblasts surrounding arterioles. The studies of coll1a1+ cells in the neonatal kidney also provide evidence that pericytes are the major precursor cell of myofibroblasts. As presented, we cannot exclude in the adult kidney a second population of kidney cells that contributes to myofibroblasts that in the normal kidney does not initially express coll1a1-GFP, but subsequently induces GFP expression following injury. It is possible that small numbers of coll1a1 negative pericytes exist in the normal adult kidney. Small numbers of PDGFRβ+, Coll1a1 negative cells were noted in the kidney interstitium in normal adult kidney but not seen in neonatal kidney. The identity of these cells has not been established but PFGFRβ is not specific for pericytes/myofibroblasts. Although we cannot exclude transdifferentiation of endothelial cells into myofibroblasts, we did not record any examples of CD31+ endothelial cells inducing GFP expression in coll-GFP mice. Thus we have accounted for all of the major cell types (epithelial cells and leukocytes) that could contribute to the myofibroblast population in the diseased kidney. Precisely a pericyte lies within the EBM and forms peg and socket points of contact with the apposing endothelial cell. This definition has derived in large part from studies of the neonatal retina where the ratio of pericytes to endothelial cells is 1.0. In the adult kidney we found that that ratio of pericytes to endothelial cells was significantly lower, at 0.4, and that not all of the pericytes were completely within the EBM. However, nearly all showed evidence of processes extending through the CBM and forming pedicle-like attachments directly to the underlying endothelial cell. In electron microscopic studies of rat kidney, similar cells were named cortical interstitial fibroblasts.13 In this context it is worth noting that several recent studies have also implicated an endogenous ‘fibroblast’ in the normal kidney as a precursor to the myofibroblast, though none has used kinetic modeling or genetic fate mapping.32,33,34 The fact that pericytes are a major source of myofibroblasts serves to readjust the focus of fibrosis research to the vasculature. Rather than epithelial injury serving as the driving force for fibrosis, our studies lead one to speculate that in fact vascular injury or vascular factors are the most likely triggers for pericyte migration and differentiation into myofibroblasts. Indeed, UUO of the kidney is known to result in down-regulation of renal blood flow and glomerular filtration rate, suggesting that circulating factors may be important triggers of pericyte migration. Understanding the signals between injured or ischemic endothelium and neighboring pericytes requires further research. Pericytes have been reported to serve as paracrine cells supporting vascular integrity, and providing important angiogenic factors including Angiopoietin-1 and -2.12,23,35 A lack of pericytes has been associated with aneurysm formation and spontaneous hemorrhage.27 PDGF signaling from endothelial cells to pericytes is necessary for pericyte recruitment along developing capillaries and vascular stabilization. Recent studies in the eye suggest that pericytes and macrophages may cooperate to delete endothelial cells during scheduled developmental vascular regression.23 In these studies pericyte release of angiopoietin-2 is necessary for withdrawal of a survival signal to the endothelial cell. Fibrotic injury has been associated with loss of capillaries in various settings following in some cases by aberrant revascularization. This is notable because in the kidney, fibrosis is associated with a reduction in peritubular capillaries.36 Furthermore, in diabetic vascular disease of the retina, pericyte loss has been found to be an important initiating factor in the development of the vascular abnormalities that constitute diabetic retinopathy.26 Thus one central question is whether the development of fibrosis results in effective pericyte loss from peritubular capillaries in the kidney, and this effective pericyte loss is a cause for peritubular capillary loss, and the consequent chronic ischemia observed in many chronic kidney diseases. PDGFRβ has been used as a marker for pericytes and has been implicated as an important receptor for recruitment and survival of pericytes by paracrine secretion of PDGFB by endothelial cells. All pericytes in the healthy adult kidney express PDGFRβ, and all myofibroblasts continue to express PDGFRβ. PDGF secretion has been implicated as an autocrine growth factor for myofibroblasts in vitro, but its role in vivo in the initiation and progression of fibrosis in the kidney is less clear,37 although in skin wound-healing, PDGFRβ blockade has been reported to delay wound closure.38 Macrophages are necessary for proliferation of kidney fibroblasts and induction of matrix deposition.39 Future studies should determine whether macrophage delivered PDGF is important in the initiation of fibrosis and pericyte differentiation. NG2 has been reported to be a marker of pericytes in the eye and brain, but reports indicate NG2 is expressed only by active pericytes, reports that are consistent with our findings in the kidney.12 Our studies show that quiescent pericytes down-regulate and lose pericyte markers, only acquiring them after injury-induced activation. The transcription factor S100A4 has been strongly implicated in the development of fibrosis in the kidney.40 However our studies identify S100A4 in macrophages and not in collagen producing cells. We have previously demonstrated an important role for macrophages in the development of fibrosis in the kidney and other organs.10,39 The mechanism requires macrophage signaling to myofibroblasts because macrophages do not generate collagen matrix themselves. One explanation for the previously reported role of S100A4 in fibrosis is that it is an important transcription factor in the development of profibrotic macrophages. Further studies will be required to elucidate whether that is the mechanism of action of S100A4. Many of the genes that are postulated to regulate the development of fibrosis have been studied in epithelial cells undergoing EMT in vitro,41,42,43 and some substantiated in vivo. To identify potential regulators of pericyte differentiation into fibroblasts we selected candidate transcription factors. Twist transcripts were not regulated by differentiation, but although pericytes had transcripts for Snai1 and Id1, they were consistently up-regulated in myofibroblasts compared with pericytes, and Bmp-7 was down-regulated in myofibroblasts compared with pericytes, consistent with their reported roles in the development of fibrosis. Further studies will be required to determine the precise role of these transcription factors and cell signaling molecules in pericyte differentiation and migration. Although kidney fibrosis research has focused on epithelial cells as the cause of fibrosis, our findings that pericytes are the source of myofibroblasts may not be surprising. There are reports that pericytes can differentiate into vascular smooth muscle cells, fibroblasts, osteoblasts, adipocytes, and chondrocytes.12,44 In disease states pericyte to osteoblast differentiation has been suggested to contribute to ectopic calcification. In fibrotic skin diseases, pericytes have been identified as the primary source of fibroblasts,45 and in the liver and pancreas, Stellate cells lie in apposition to endothelial cells and may be a specialized pericyte.46 It is interesting that podocytes express coll1a1-GFP, suggesting they may have the capacity to play a more predominant role in glomerular scarring than previously thought. In murine nephrotoxic nephritis in the coll-GFP mouse, both mesangial cells and podocytes generate coll1a1 transcripts (manuscript in preparation). The glomerular basement membrane in health, does not contain fibrillary collagen, although may contain minor amounts of non-fibrillary collagen-type I, α chain,47,48 most likely synthesized by podocytes. The fact that podocytes share coll1a1-GFP expression with pericytes points to a pericyte-like role for podocytes in endothelial health. It is interesting therefore that genetic deletion of vascular endothelial growth factor in podocytes only, is sufficient to trigger endothelial death and severe thrombotic glomerular injury.49 Our studies confirmed the existence of a cell defined as fibrocyte, which did not express αSMA. Although we detected fibrocytes in injured kidney, spleen, and BM they were not detected in the circulation, suggesting that fibrocytes differentiate locally into coll1a1+ cells from either pre-existing cells or from circulating leukocytes such as a monocyte. Further, the pattern of recruitment in injury to spleen and BM and lack of sustained recruitment to kidney and no recruitment to skin wound suggest that they are acute phase respondent cells, not fibroblasts. Rather than lay down fibrotic matrix their presence in the spleen combined with highly expressed antigen presentation molecules suggests they function more like dendritic cells than fibroblasts. Nevertheless, fibrocytes appear to constitute a novel class of myeloid dendritic cells because they lack CD11b, and express CD34. In conclusion, our studies identify a population of coll1a1+ pericytes in normal kidney that are the major source of myofibroblasts occurring in the ureteral obstruction model of kidney fibrosis. Acknowledgments Thanks to Dr. Sushrut Waikar (Harvard Medical School) for assistance with mathematical modeling, Deneen Kozoriz (HMS) for assistance with FACS sorting, Dr. William Stallcup (Burnham Inst.) for anti-NG2 and anti-PDGFRβ antibodies, Dr. Inna Gitelman (Ben Gurion Univ., Israel), Dr. Jing Yang (UCSD) for anti-Twist antibodies, and Dr. Martin Pollak (HMS) for anti-podocin and anti-synaptopodin antibodies. Footnotes Address reprint requests to Jeremy S. Duffield, Laboratory of Inflammation Research, Harvard Institutes of Medicine, 5th Floor, 4 Blackfan Circle, Boston, MA, 02115. E-mail: jduffield/at/rics.bwh.harvard.edu or Shuei-Liong Lin, E mail: linsl/at/ntumc.org. Supported by NIH grant DK73299 (J.S.D.), and grants from American Society of Nephrology (Gottschalk Award), Genzyme Renal Innovations Program, Promedior Inc. (J.S.D.), and an award from the National Taiwan Science Council NSC-095-SAF-I-564-601 (S.L.L.). These studies were presented in part at the Annual Meeting of the American Society of Nephrology, San Francisco, 2007. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||
N Engl J Med. 2001 Jul 12; 345(2):93-7.
[N Engl J Med. 2001]Kidney Int. 2005 Nov; 68(5):1956-61.
[Kidney Int. 2005]J Clin Invest. 2005 Jul; 115(7):1756-64.
[J Clin Invest. 2005]J Am Soc Nephrol. 2006 Mar; 17(3):775-82.
[J Am Soc Nephrol. 2006]J Clin Invest. 2002 Aug; 110(3):341-50.
[J Clin Invest. 2002]J Clin Invest. 2002 Aug; 110(3):341-50.
[J Clin Invest. 2002]Hepatology. 2003 Feb; 37(2):267-76.
[Hepatology. 2003]Gene Expr. 1999; 8(3):151-63.
[Gene Expr. 1999]Hepatology. 2003 Feb; 37(2):267-76.
[Hepatology. 2003]Gene Expr. 1999; 8(3):151-63.
[Gene Expr. 1999]J Clin Invest. 2005 Jul; 115(7):1743-55.
[J Clin Invest. 2005]J Clin Invest. 2005 Jan; 115(1):56-65.
[J Clin Invest. 2005]J Clin Invest. 2005 Jul; 115(7):1743-55.
[J Clin Invest. 2005]J Clin Invest. 2005 Jan; 115(1):56-65.
[J Clin Invest. 2005]J Clin Invest. 2005 Jul; 115(7):1743-55.
[J Clin Invest. 2005]J Clin Invest. 2005 Jul; 115(7):1743-55.
[J Clin Invest. 2005]J Clin Invest. 2005 Jan; 115(1):56-65.
[J Clin Invest. 2005]J Clin Invest. 2008 May; 118(5):1657-68.
[J Clin Invest. 2008]Hepatology. 2003 Feb; 37(2):267-76.
[Hepatology. 2003]Gene Expr. 1999; 8(3):151-63.
[Gene Expr. 1999]Circ Res. 2005 Sep 16; 97(6):512-23.
[Circ Res. 2005]Kidney Int. 1994 Mar; 45(3):709-20.
[Kidney Int. 1994]Anat Embryol (Berl). 1996 Apr; 193(4):303-18.
[Anat Embryol (Berl). 1996]J Immunol. 2001 Jun 15; 166(12):7556-62.
[J Immunol. 2001]Blood. 2000 Feb 1; 95(3):855-62.
[Blood. 2000]Cell Tissue Kinet. 1984 Jul; 17(4):401-10.
[Cell Tissue Kinet. 1984]Blood. 1992 Nov 1; 80(9):2336-43.
[Blood. 1992]Circ Res. 2005 Sep 16; 97(6):512-23.
[Circ Res. 2005]Am J Pathol. 2004 Oct; 165(4):1301-13.
[Am J Pathol. 2004]J Cell Biol. 2001 Apr 30; 153(3):543-53.
[J Cell Biol. 2001]Microvasc Res. 2001 Mar; 61(2):160-5.
[Microvasc Res. 2001]Microvasc Res. 2002 Jan; 63(1):129-34.
[Microvasc Res. 2002]Am J Pathol. 2004 Oct; 165(4):1301-13.
[Am J Pathol. 2004]J Cell Biol. 2001 Apr 30; 153(3):543-53.
[J Cell Biol. 2001]Microvasc Res. 2001 Mar; 61(2):160-5.
[Microvasc Res. 2001]Microvasc Res. 2002 Jan; 63(1):129-34.
[Microvasc Res. 2002]Circ Res. 2005 Sep 16; 97(6):512-23.
[Circ Res. 2005]Cell. 2004 Jun 25; 117(7):927-39.
[Cell. 2004]EMBO J. 2006 Nov 29; 25(23):5603-13.
[EMBO J. 2006]J Biol Chem. 2007 May 11; 282(19):13934-43.
[J Biol Chem. 2007]Kidney Int. 1994 Mar; 45(3):709-20.
[Kidney Int. 1994]Histochem Cell Biol. 2008 Jul; 130(1):141-55.
[Histochem Cell Biol. 2008]Histochem Cell Biol. 2005 Jun; 123(4-5):335-46.
[Histochem Cell Biol. 2005]Virchows Arch. 2005 Feb; 446(2):164-76.
[Virchows Arch. 2005]Circ Res. 2005 Sep 16; 97(6):512-23.
[Circ Res. 2005]Development. 2007 Dec; 134(24):4449-58.
[Development. 2007]J Clin Invest. 2002 Dec; 110(11):1619-28.
[J Clin Invest. 2002]Science. 1997 Jul 11; 277(5323):242-5.
[Science. 1997]Curr Opin Nephrol Hypertens. 2004 Jan; 13(1):1-7.
[Curr Opin Nephrol Hypertens. 2004]J Am Soc Nephrol. 2003 Oct; 14(10):2544-55.
[J Am Soc Nephrol. 2003]Am J Pathol. 2006 Dec; 169(6):2254-65.
[Am J Pathol. 2006]Am J Pathol. 2005 Nov; 167(5):1207-19.
[Am J Pathol. 2005]Circ Res. 2005 Sep 16; 97(6):512-23.
[Circ Res. 2005]Mol Ther. 2001 Feb; 3(2):149-59.
[Mol Ther. 2001]J Clin Invest. 2005 Jan; 115(1):56-65.
[J Clin Invest. 2005]Am J Pathol. 2005 Nov; 167(5):1207-19.
[Am J Pathol. 2005]Nat Cell Biol. 2008 Mar; 10(3):295-305.
[Nat Cell Biol. 2008]Biochem Biophys Res Commun. 2007 Oct 12; 362(1):63-8.
[Biochem Biophys Res Commun. 2007]J Am Soc Nephrol. 2007 Feb; 18(2):449-60.
[J Am Soc Nephrol. 2007]Circ Res. 2005 Sep 16; 97(6):512-23.
[Circ Res. 2005]Circ Res. 2005 May 13; 96(9):930-8.
[Circ Res. 2005]Arthritis Res Ther. 2005; 7(5):R1113-23.
[Arthritis Res Ther. 2005]FASEB J. 1991 Mar 1; 5(3):271-7.
[FASEB J. 1991]Kidney Int. 2002 Aug; 62(2):383-91.
[Kidney Int. 2002]